Skip to main content
Journal cover image

Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.

Publication ,  Journal Article
van Diepen, S; Newby, LK; Lopes, RD; Stebbins, A; Hasselblad, V; James, S; Roe, MT; Ezekowitz, JA; Moliterno, DJ; Neumann, F-J; Reist, C ...
Published in: Int J Cardiol
October 3, 2013

BACKGROUND: Plaque rupture, acute ischemia, and necrosis in acute coronary syndromes are accompanied by concurrent pro- and anti-inflammatory cascades. Whether STEMI clinical prediction models can be improved with the addition of baseline inflammatory biomarkers remains unknown. METHODS: In an APEX-AMI trial substudy, 772 patients had a panel of 9 inflammatory serum biomarkers, high sensitivity C reactive protein (hsCRP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured at baseline after randomization. Baseline biomarkers were incorporated into a clinical prediction model for a composite of 90-day death, shock, or heart failure. Incremental prognostic value was assessed using Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). RESULTS: Individually, several biomarkers were independent predictors of clinical outcome: hsCRP (hazard ratio [HR] 1.12; 95% confidence interval [CI], 1.03-1.21; p=0.007, per doubling), NT-proBNP (HR 1.14; 95% CI, 1.06-1.23; p<0.001, per doubling), interleukin (IL)-6 (HR 1.26; 95% CI, 1.12-1.41;p<0.001, per doubling), and inducible protein-10 (IP-10) (HR 0.86; 95% CI, 0.76-0.98; p<0.025, per doubling). The addition of baseline NT-proBNP (NRI 8.6%, p=0.028; IDI 0.030, p<0.001) and IL-6 (NRI 8.8%, p=0.012; IDI 0.036, p<0.001) improved the clinical risk prediction model and the addition of hsCRP (NRI 6.5%, p=0.069; IDI 0.018, p=0.004) yielded minimal improvement. After incorporating NT-proBNP into the model, the remaining biomarkers added little additional predictive value. CONCLUSIONS: Multiple inflammatory biomarkers independently predicted 90-day death, shock or heart failure; however, they added little value to a clinical prediction model that included NT-proBNP. Future studies of inflammatory biomarkers in STEMI should report incremental value in a prediction model that includes NT-proBNP.

Duke Scholars

Published In

Int J Cardiol

DOI

EISSN

1874-1754

Publication Date

October 3, 2013

Volume

168

Issue

3

Start / End Page

2127 / 2133

Location

Netherlands

Related Subject Headings

  • United States
  • Sweden
  • Single-Chain Antibodies
  • Shock, Cardiogenic
  • Prognosis
  • Predictive Value of Tests
  • Percutaneous Coronary Intervention
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Myocardial Infarction
 

Citation

APA
Chicago
ICMJE
MLA
NLM
van Diepen, S., Newby, L. K., Lopes, R. D., Stebbins, A., Hasselblad, V., James, S., … APEX AMI Investigators, . (2013). Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol, 168(3), 2127–2133. https://doi.org/10.1016/j.ijcard.2013.01.004
Diepen, Sean van, L Kristin Newby, Renato D. Lopes, Amanda Stebbins, Vic Hasselblad, Stefan James, Matthew T. Roe, et al. “Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.Int J Cardiol 168, no. 3 (October 3, 2013): 2127–33. https://doi.org/10.1016/j.ijcard.2013.01.004.
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, et al. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol. 2013 Oct 3;168(3):2127–33.
van Diepen, Sean, et al. “Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.Int J Cardiol, vol. 168, no. 3, Oct. 2013, pp. 2127–33. Pubmed, doi:10.1016/j.ijcard.2013.01.004.
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, Moliterno DJ, Neumann F-J, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P, APEX AMI Investigators. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol. 2013 Oct 3;168(3):2127–2133.
Journal cover image

Published In

Int J Cardiol

DOI

EISSN

1874-1754

Publication Date

October 3, 2013

Volume

168

Issue

3

Start / End Page

2127 / 2133

Location

Netherlands

Related Subject Headings

  • United States
  • Sweden
  • Single-Chain Antibodies
  • Shock, Cardiogenic
  • Prognosis
  • Predictive Value of Tests
  • Percutaneous Coronary Intervention
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Myocardial Infarction